CSL sinks to nine-year low on revenue warning, $5B write-down

May 11, 2026 06:30 AM EDT PharmaManufacturing CSL sinks to nine-year low on rev­enue warn­ing, $5B write-down Elizabeth Cairns Senior biopharma journalist CSL’s stock hit its low­est price since ear­ly 2017 on Mon­day af­ter it low­ered its full-year rev­enue guid­ance by about 4% and said it would … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER